Experimental infection and protection against ... - TI Pharma

238 Chapter 11
72. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant
circumsporozoite protein vaccine regimens against experimental Plasmodium
falciparum malaria. J Infect Dis 2001; 183:640-647.
73. Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3
month and 0, 7, and 28 day immunization schedules of malaria vaccine
RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of
Research. Vaccine 2008; 26:2191-2202.
74. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine
against Plasmodium falciparum infection in semi-immune adult men in The
Gambia: a randomised trial. Lancet 2001; 358:1927-1934.
75. Kester KE, Cummings JF, Ofori-Anyinam O et al. Randomized, double-blind,
phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in
malaria-naive adults: safety, efficacy, and immunologic associates of protection.
J Infect Dis 2009; 200:337-346.
76. Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind,
controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection
in Gambian adults. PLoS Med 2004; 1:e33.
77. Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus
ankara boost vaccine encoding thrombospondin-related adhesion protein but
not circumsporozoite protein partially protects healthy malaria-naive adults
against Plasmodium falciparum sporozoite challenge. Infect Immun 2006;
74:5933-5942.
78. Lawrence G, Cheng QQ, Reed C et al. Effect of vaccination with 3 recombinant
asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum
in non-immune volunteers. Vaccine 2000; 18:1925-1931.
79. Genton B, al-Yaman F, Betuela I et al. Safety and immunogenicity of a threecomponent
blood-stage malaria vaccine [MSP1, MSP2, RESA) against
Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-
41.
80. Genton B, D'Acremont V, Lurati-Ruiz F et al. Randomized double-blind
controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to
protect against challenge with P. falciparum. Vaccine 2010; 28:6573-6580.
81. Trape JF, Zoulani A. Malaria and urbanization in central Africa: the example of
Brazzaville. Part II: Results of entomological surveys and epidemiological
analysis. Trans R Soc Trop Med Hyg 1987; 81 Suppl 2:10-18.
82. Takala SL, Coulibaly D, Thera MA et al. Extreme polymorphism in a vaccine
antigen and risk of clinical malaria: implications for vaccine development. Sci
Transl Med 2009; 1:2ra5.
83. Rosenberg R, Wirtz RA, Schneider I, Burge R. An estimation of the number of
malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg
1990; 84:209-212.
84. Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding
behaviour and sporozoite ejection by infected Anopheles stephensi. Trans R Soc
Trop Med Hyg 1991; 85:175-180.